^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Zercepac (trastuzumab biosimilar) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/27/2020
Excerpt:
Zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
Secondary therapy:
docetaxel; paclitaxel; Aromatase inhibitor
